Fraunhofer Institute for Toxicology and Experimental Medicine

OM Pharma and Fraunhofer ITEM announce initiation of a phase Ia/Ib clinical trial evaluating safety and tolerability of OM-85-Intranasal (IN).

3 million euros allocated for research into the development of innovative technologies for brain regeneration.

Fraunhofer ITEM is one of seven research partners, led by the University of Coimbra, seeking to create better therapies for patients with neurodegenerative diseases or stroke using this technology.

Research for healthy lungs: Airway research has been a focus at Fraunhofer ITEM ever since the institute was founded. 

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.

Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.